Skip to main content

Table 2 Subgroup analysis in testosterone and DHEA

From: The effects of statins on hyperandrogenism in women with polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials

Subgrouped by No. of trials WMD (95% CI) P Value P for heterogeneity I2 (%) P for between Subgroup heterogeneity
Testosterone
 total 9 -0.47[−0.76,-0.18] 0.002 0.002 68  
 Statin type       0.86
  Simvastatin 6 -0.48 [−0.77, − 0.18] 0.002 0.002 66  
  Atorvastatin 3 −0.39 [−1.38, 0.61] 0.45 0.007 80  
 Contol type       0.90
  Placebo 5 -0.39 [−0.86, 0.09] 0.11 0.008 71  
  Metformin 3 −0.43 [− 0.84, − 0.02] 0.04 0.06 65  
DHEA
 total 7 −0.51 [− 0.97, − 0.05] 0.03 < 0.001 84  
 Statin type       0.79
  Simvastatin 5 −0.46 [−1.02, 0.09] 0.10 < 0.001 89  
  Atorvastatin 2 −0.62 [−1.70, 0.45] 0.25 < 0.001 67  
 Contol type       0.70
  Placebo 3 −0.49 [−1.44, 0.46] 0.31 < 0.001 93  
  Metformin 3 −0.70 [−1.20, − 0.21] 0.005 0.15 47